Sunday - November 16, 2025
AstraZeneca: FARXIGA Improved Symptom Burden And Health-Related Quality Of Life In Patients With Mildly Reduced Or Preserved Ejection Fraction In DELIVER Phase III Trial
November 08, 2022
WILMINGTON, Delaware, Nov. 8 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Nov. 7, 2022:

* * *

- Results presented at American Heart Association (AHA) Scientific Sessions 2022 and being published in the Journal of the American College of Cardiology

- Clinical benefits were observed within two weeks with FARXIGA, highlighting the importance of early treatment initiation

* * *

New findings . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products